Connor, Clark & Lunn Investment Management (CC&L)’s Fulgent Genetics FLGT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.81M	Sell	302,564 -72,261	-19%	-$1.57M	0.01%	693
2025 Q4	$9.85M	Buy	374,825 +43,299	+13%	+$1.12M	0.03%	468
2025 Q3	$7.49M	Buy	331,526 +26,346	+9%	+$543K	0.02%	477
2025 Q2	$6.07M	Buy	305,180 +55,521	+22%	+$1.08M	0.02%	524
2025 Q1	$4.22M	Buy	249,659 +123,702	+98%	+$2.11M	0.02%	541
2024 Q4	$2.33M	Buy	125,957 +112,011	+803%	+$2.19M	0.01%	682
2024 Q3	$303K	Buy	+13,946	New	+$312K	﹤0.01%	1236
2022 Q1	–	Sell	-6,649	Closed	-$669K	–	1089
2021 Q4	$669K	Buy	+6,649	New	+$584K	﹤0.01%	747

Other funds holding FLGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s FLGT Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Fulgent Genetics (FLGT) stake by 19% in Q1 2026, selling an estimated $1.57M and leaving 302,564 shares worth $4.81M. The position accounts for 0.01% of the portfolio, ranked #693.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in FLGT in Q4 2021 and has held it in 8 quarters since. The position peaked at $9.85M in Q4 2025. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 302,564 shares of Fulgent Genetics worth $4.81M as of Q1 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 72,261 Fulgent Genetics shares in Q1 2026, an estimated $1.57M.
Fulgent Genetics made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #693 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Fulgent Genetics in Q4 2021 and has held it in 8 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Fulgent Genetics position peaked at $9.85M in Q4 2025.
157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.